Objectives: Abatacept retention rates were evaluated in the French cohort in the prospective ACTION study (2010-2013), which included patients with moderate-to-severe rheumatoid arthritis managed in everyday clinical practice and started on intravenous abatacept therapy.
Methods: Two-year abatacept retention rates were evaluated in 455 patients classified according to treatment line, body mass index (BMI), and status for rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA).
Results: After 2 years, the overall abatacept retention rate was 44%. The retention rate was non-significantly higher in the patients with vs. without a history of unresponsiveness to at least one biologic (48.1% vs. 41.8%, respectively). No significant retention rate differences were found across BMI categories (444 patients; <25, 45.5%; ≥25 to <30, 48.9%; and ≥30, 36.6%). Neither were any significant differences demonstrated according to RF and ACPA status (RF+ and ACPA+, 45.7%; RF+ or ACPA+, 43.8%; and FR- and ACPA-, 39.1%).
Conclusion: The 44% 2-year retention rate in the French ACTION cohort supports the usefulness of abatacept therapy. In this study, retention was not associated with treatment line, BMI, or antibody status.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jbspin.2019.07.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical presentation and treatment response in ACPA-negative rheumatoid arthritis.
Joint Bone Spine
November 2024
UMR 1227 Lymphocytes B, Auto-immunité et Immunothérapies, University Brest, Inserm, CHU de Brest, Brest, France.
Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation and potential extra-articular manifestations. This review compares the presentation and treatment response between anti-citrullinated protein antibodies (ACPA)-positive and ACPA-negative RA patients. The incidence of seronegative RA (rheumatoid factor [RF]-negative and ACPA-negative) has increased in recent decades, emphasizing the need for new diagnostic biomarkers.
View Article and Find Full Text PDFIncidence and risk factors of discontinuation of tofacitinib and biologic disease-modifying anti-rheumatic drugs among patients with rheumatoid arthritis: A population-based cohort study.
Clin Rheumatol
December 2024
Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Xitun District, No. 1650, Sec. 4, Taiwan Blvd., Taichung, 40705, Taiwan.
Article Synopsis
- This study analyzed the discontinuation rates of tofacitinib and various biologic DMARDs in 5,008 rheumatoid arthritis patients between 2014 and 2020.
- Tofacitinib had the lowest discontinuation rate (21.8%) compared to etanercept (43.27%) and showed lower risks than other bDMARDs.
- Key factors influencing drug discontinuation included higher steroid dosages and existing connective tissue diseases increasing risk, while methotrexate use decreased the likelihood of discontinuation.
Aim: To evaluate real-world abatacept retention and clinical outcomes in patients with rheumatoid arthritis in Taiwan.
Methods: This prospective, observational study enrolled patients with rheumatoid arthritis aged ≥20 years who received abatacept in real-world practice. The primary endpoint was the abatacept retention rate at 24 months.
Subsequent biologic and targeted synthetic disease modifying anti rheumatic drugs after fulfilling difficult-to-treat rheumatoid arthritis criteria: a survival analysis.
Clin Rheumatol
September 2024
Rheumatology Department, Hospital Universitario La Paz, Paseo de La Castellana 261, Madrid, Spain.
Article Synopsis
- The study evaluates the effectiveness and survival rates of various biologic and targeted-synthetic drugs for patients with difficult-to-treat rheumatoid arthritis (D2TRA).
- Out of 122 patients analyzed, 61.5% continued treatment with better survival linked to drugs like rituximab, while others like abatacept showed poorer survival rates.
- Key factors influencing treatment discontinuation included the choice of the drug and higher Disease Activity Score (DAS28) six months post-treatment initiation.
Retention rate of abatacept in rheumatoid arthritis patients in a real-life setting: results from a monocentric cohort.
Reumatismo
June 2024
Rheumatology Unit, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome.
Objective: Data from trials demonstrated that abatacept (ABA) has a good safety and efficacy profile in treating rheumatoid arthritis. We have studied the retention rate of ABA in a real-life cohort of patients with rheumatoid arthritis.
Methods: This is a monocentric, retrospective study including patients with rheumatoid arthritis classified by the American College of Rheumatology/European League Against Rheumatism 2010 criteria who started treatment with ABA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!